Haemonetics Corporation (HAE)

Haemonetics' stock price has experienced fluctuations over the past six months. The share price was $56.24 as of April 1, 2026, a decline from the previous year. Key events include earnings reports, where the company beat revenue expectations but saw a sales decline, and FDA approvals for its VASCADE MVP XL and NexSys PCS systems. Analyst rating changes, such as Citi lowering its price target, have also impacted the stock.

Demand seasonality for Haemonetics' products is observed in plasma collection volumes. U.S. plasma collection volumes grew in line with historical seasonality. International demand for source plasma is also expanding. Product revenue is generally driven by the demand for disposable blood component collection and processing sets and the related equipment.

Haemonetics Corporation is a global healthcare company specializing in medical technology solutions. It operates within the Healthcare sector, focusing on blood management needs across Plasma, Blood Center, and Hospital segments. The Plasma segment offers automated plasma collection systems and donor management software. The Blood Center segment provides solutions for automated blood collection, processing, and testing. The Hospital segment includes Interventional Technologies and Blood Management Technologies, featuring vascular closure systems, hemostasis management systems, and surgical blood salvage devices.

Haemonetics has a significant global presence with offices in 16 countries and markets its products in over 50 countries. Revenue is nearly equally derived from Asia, Europe, and the Americas. The company's headquarters are located in Boston, Massachusetts, USA.

Haemonetics maintains a reputation as a global leader in blood management solutions and innovative medical technology. Recent FDA approvals and the acquisition of Attune Medical have enhanced its reputation. Financial performance, including a year-on-year sales decline, could be a point of scrutiny. Being selected as the exclusive supplier of plasma collection solutions to the Japanese Red Cross positively impacts its international reputation.

Haemonetics Corporation is a publicly traded company with a diverse ownership structure including institutional, retail, and individual investors. Institutional investors hold a substantial portion of the stock. Major institutional owners include BlackRock, Inc. and Vanguard Group Inc. Approximately 83.79% of the company's stock is owned by Institutional Investors, 1.39% by Insiders, and 14.83% by Public Companies and Individual Investors.